Stay updated with breaking news from Statutory Scheme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ABPI response to government Statutory Scheme riseThe government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject to the Statutory Scheme for branded medicines from 24.4% to 27.5% [1].In February, the Association of the British Pharmaceutical Industry warned that the propose...
The ABPI and Lilly have responded to the UK government’s confirmed plans to increase the payment percentage in the Statutory Scheme.
The Department of Health and ICAEW have reviewed the audit reports required under the scheme to ensure they continue to comply with International Standards on Auditing (UK).
The ABPI has urged immediate government action is needed against the planned UK statutory revenue clawback rate rise for branded medicines.
Major industry names depart leaving UK pricing deal in serious jeopardy - News - PharmaTimes